Reshaping Rheumatology – The era of biosimilars
In this CPD-accredited report, Professor Peter Nash of Griffith University, Australia, discusses perceptions and misconceptions with regard to biosimilars as therapy for rheumatological disease
You will learn:
• Biosimilars are highly similar to the reference biologic
• There is substantial evidence showing no inferiority between originator biologics and biosimilars in terms of efficacy and safety
• A single or double switch between originators and biosimilars is safe
• Indication extrapolation is permissible only when certain criteria have been met
• Immunogenicity to the reference biologic will cross-react with the biosimilar.
WEBINAR HELD ON 19 JUNE 2021
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report.
Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don’t upload these yourself.
To access this module, please register or login: